MedTrace Logo

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

NCT02450682 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-01-18

No results posted yet for this study

Summary

This study is being done to determine if apixaban is more safe, when compared to warfarin, at reducing the risk of bleeding during CIED procedures.

Conditions

Interventions

DRUG

Apixaban

Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change

DRUG

Warfarin

Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change

Sponsors & Collaborators

Principal Investigators

  • Yong-Mei Cha, MD · Mayo Clinic

  • Samuel Asirvatham, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-01-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450682 on ClinicalTrials.gov